Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Arcturus Therapeutics's total assets was $215.32M at Sep 30, 2026. For fiscal 2025 it was $271.15M, down 21.2% from the year before. The highest annual figure on record is $476.46M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $271.15M | -21.2% |
| FY2024 | Dec 31, 2024 | $344.07M | -19.9% |
| FY2023 | Dec 31, 2023 | $429.40M | -4.7% |
| FY2022 | Dec 31, 2022 | $450.39M | +14.7% |
| FY2021 | Dec 31, 2021 | $392.81M | -17.6% |
| FY2020 | Dec 31, 2020 | $476.46M | +480.0% |
| FY2019 | Dec 31, 2019 | $82.14M | +85.9% |
| FY2018 | Dec 31, 2018 | $44.20M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $215.32M | -23.7% |
| Q2 FY2026 | Jun 30, 2026 | $224.31M | -27.5% |
| Q1 FY2026 | Mar 31, 2026 | $245.41M | -26.0% |
| Q4 FY2025 | Dec 31, 2025 | $271.15M | -21.2% |
| Q3 FY2025 | Sep 30, 2025 | $282.34M | -23.8% |
| Q2 FY2025 | Jun 30, 2025 | $309.27M | -20.4% |
| Q1 FY2025 | Mar 31, 2025 | $331.79M | -20.8% |
| Q4 FY2024 | Dec 31, 2024 | $344.07M | -19.9% |
| Q3 FY2024 | Sep 30, 2024 | $370.65M | -19.0% |
| Q2 FY2024 | Jun 30, 2024 | $388.61M | -9.8% |
| Q1 FY2024 | Mar 31, 2024 | $418.85M | -11.0% |
| Q4 FY2023 | Dec 31, 2023 | $429.40M | -4.7% |
| Q3 FY2023 | Sep 30, 2023 | $457.65M | +55.9% |
| Q2 FY2023 | Jun 30, 2023 | $430.65M | +27.8% |
| Q1 FY2023 | Mar 31, 2023 | $470.86M | +37.7% |
| Q4 FY2022 | Dec 31, 2022 | $450.39M | +14.7% |
| Q3 FY2022 | Sep 30, 2022 | $293.63M | -32.4% |
| Q2 FY2022 | Jun 30, 2022 | $337.01M | -24.9% |
| Q1 FY2022 | Mar 31, 2022 | $341.99M | -29.0% |
| Q4 FY2021 | Dec 31, 2021 | $392.81M | -17.6% |
| Q3 FY2021 | Sep 30, 2021 | $434.54M | +34.7% |
| Q2 FY2021 | Jun 30, 2021 | $448.81M | +199.3% |
| Q1 FY2021 | Mar 31, 2021 | $481.47M | +567.7% |
| Q4 FY2020 | Dec 31, 2020 | $476.46M | +480.0% |
| Q3 FY2020 | Sep 30, 2020 | $322.52M | +269.8% |
| Q2 FY2020 | Jun 30, 2020 | $149.94M | +111.4% |
| Q1 FY2020 | Mar 31, 2020 | $72.10M | +63.1% |
| Q4 FY2019 | Dec 31, 2019 | $82.14M | – |
| Q3 FY2019 | Sep 30, 2019 | $87.22M | – |
| Q2 FY2019 | Jun 30, 2019 | $70.94M | – |
| Q4 FY2018 | Dec 31, 2018 | $44.20M | – |
See a number that looks wrong?